These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 10583026

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Food increases the bioavailability of tolterodine but not effective exposure.
    Olsson B, Brynne N, Johansson C, Arnberg H.
    J Clin Pharmacol; 2001 Mar; 41(3):298-304. PubMed ID: 11269570
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.
    Hua TC, Pan A, Chan C, Poo YK, Skinner MH, Knadler MP, Gonzales CR, Wise SD.
    Br J Clin Pharmacol; 2004 May; 57(5):652-6. PubMed ID: 15089819
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
    Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC.
    Curr Med Chem; 2009 May; 16(33):4481-9. PubMed ID: 19835561
    [Abstract] [Full Text] [Related]

  • 11. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
    Simon HU, Malhotra B.
    Swiss Med Wkly; 2009 Mar 07; 139(9-10):146-51. PubMed ID: 19145494
    [Abstract] [Full Text] [Related]

  • 12. The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
    Olsson B, Landgren BM.
    Clin Ther; 2001 Nov 07; 23(11):1876-88. PubMed ID: 11768839
    [Abstract] [Full Text] [Related]

  • 13. Serum protein binding of tolterodine and its major metabolites in humans and several animal species.
    Påhlman I, Gozzi P.
    Biopharm Drug Dispos; 1999 Mar 07; 20(2):91-9. PubMed ID: 10206324
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J, Goosen TC, Tse S, Yamagami H, Malhotra B.
    J Clin Pharmacol; 2019 Nov 07; 59(11):1505-1518. PubMed ID: 31090092
    [Abstract] [Full Text] [Related]

  • 19. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
    Dmochowski R, Chen A, Sathyan G, MacDiarmid S, Gidwani S, Gupta S.
    J Clin Pharmacol; 2005 Aug 07; 45(8):961-8. PubMed ID: 16027408
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.